ANP 801
Alternative Names: ANP-801Latest Information Update: 30 Oct 2020
At a glance
- Originator ANP Technologies
- Class Antineoplastics; Oligonucleotides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 28 Oct 2020 ANP 801 is available for licensing as of 28 Oct 2020. https://www.anptinc.com/
- 28 Oct 2020 Preclinical trials in Cancer in USA (unspecified route)
- 28 Oct 2020 ANP Technologies plans to submit an IND application for ANP 801 for Cancer (ANP Technologies website, October 2020)